Glucagon-like peptide-1 agonist

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes.[1] One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia.[2]

There is some concern over the safety profile of these drugs due to proliferative effects in the pancreas.[3]

Approved GLP-1 agonists:

Under investigation: [1]

These agents work in the same pathway as DPP-4 inhibitors but are generally considered more potent.[8]